Diclofenac - Assertio Therapeutics

Drug Profile

Diclofenac - Assertio Therapeutics

Alternative Names: Lynxorb™; ProSorb-D™; XP 21L; Zipsor

Latest Information Update: 20 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AAIPharma
  • Developer Assertio Therapeutics
  • Class Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Phenylacetates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Prostaglandin synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acute pain

Most Recent Events

  • 15 Aug 2018 Depomed is now called Assertio Therapeutics
  • 28 Feb 2018 Depomed has patent protection for Diclofenac (Zipsor®) in USA
  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Acute pain(In adolescents) in USA (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top